By studying the simple nematode worm Caenorhabditis elegans, a team led by scientists at the University of Kent discovered a transcription factor—a protein involved in turning genes on and off—that seems to act as a master controller of the sense of hunger and related eating or resting behaviors in humans.
Diving deeper into the cancer testing market, Agilent Technologies aims to pick up liquid biopsy developer Resolution Bioscience for $550 million in upfront cash.
From the big screen, to the small screen, to the MRI—Disney teams with Philips to bring its characters to pediatric imaging
Getting an MRI has never been a walk in the park. Being fed into a large, almost unnaturally heavy machine powered by unseen forces—and almost always kept in the basement—is understandably unsettling, especially for a child. But it’s something Philips hopes to make a little bit brighter.
Moderna has poached major stem cell researcher Jonathan Hoggatt, Ph.D., to lead its hematology R&D as it gears up for a future outside of COVID vaccines.
Prime time for Five Prime as Amgen snaps up this once-moribund biotech for $1.9B and its phoenix-from-the-flames cancer asset
After seeing the biotech’s shares soar 300% late last year on positive new data for its midstage gastric cancer program, Amgen has stepped in with a $1.9 billion deal to buy out long-suffering Five Prime Therapeutics.
Another phase 3 clinical trial of Eli Lilly’s tirzepatide in Type 2 diabetics has met its primary endpoint. The dual GIP/GLP-1 agonist beat Novo Nordisk’s semaglutide against multiple measures, although recent data on another dose of the rival drug suggest Lilly has a fight on its hands.
Like so many in the world, President Joe Biden has been personally hit by a cancer death after the loss of his son Beau in 2015 to a brain tumor.
Exscientia has raised $100 million to further develop its artificial intelligence drug discovery platform while advancing its proprietary pipeline into clinical trials. The series C saw Exscientia add BlackRock to an investor syndicate already dotted with big names.
ING’s Garvey says the 10-year note yield could rise above 2% this year
Shares of Walmart Inc. WMT sank 0.05% to $127.53 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 1.34% to 3,768.47 and Dow Jones Industrial Average DJIA falling 1.11% to 30,924.14. This was the stock’s third consecutive day of losses. Walmart Inc. closed $26.13 short of its 52-week high ($153.66), which the company achieved on December 1st.